| Specificity and targeted delivery of drugs can be achieved |
Unintended penetration and translocation of nanocarriers to the blood–brain barrier, lungs results in toxicity |
| Improved tumour penetration for anticancer drugs |
Nanocarriers can change in shape and size resulting in varied physicochemical interactions and activity |
| Enhanced Permeability and Retention can permit the passive accumulation |
Suboptimal delivery due to heterogeneities of nanocarriers in vascular permeability |
| Enhanced bioavailability and efficacy |
Uptake by RES can reduce the efficacy |
| Controlled delivery of drugs with low dose |
Limited availability of animal models |
